- Previous Close
4.4200 - Open
4.4200 - Bid 4.5300 x 165400
- Ask 4.7600 x 161000
- Day's Range
4.4200 - 4.7600 - 52 Week Range
3.9800 - 11.2000 - Volume
400 - Avg. Volume
249 - Market Cap (intraday)
82.235M - Beta (5Y Monthly) 1.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7400 - Earnings Date Oct 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
www.4sc.comRecent News: VSC.F
View MorePerformance Overview: VSC.F
Trailing total returns as of 11/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VSC.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VSC.F
View MoreValuation Measures
Market Cap
44.70M
Enterprise Value
40.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
124.52
Price/Book (mrq)
40.79
Enterprise Value/Revenue
112.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.05%
Return on Equity (ttm)
-154.90%
Revenue (ttm)
359k
Net Income Avi to Common (ttm)
-7.53M
Diluted EPS (ttm)
-0.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.43M
Total Debt/Equity (mrq)
291.79%
Levered Free Cash Flow (ttm)
--